State Street Corp. Updates Passive Stake in Kezar Life Sciences
Ticker: KZR · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1645666
| Field | Detail |
|---|---|
| Company | Kezar Life Sciences, INC. (KZR) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still owns Kezar Life Sciences stock, signaling continued institutional interest.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Kezar Life Sciences Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, confirming their continued passive investment in the pharmaceutical company. For investors, this means a significant institutional player maintains a stake, which can be a signal of confidence, though the exact percentage of ownership is not detailed in this excerpt.
Why It Matters
This filing confirms State Street Corporation's ongoing passive investment in Kezar Life Sciences, which can provide a degree of institutional validation for current and prospective shareholders.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate change in company operations or significant market risk.
Analyst Insight
Investors should view this as a routine disclosure of an institutional holding, confirming State Street's continued, passive interest in Kezar Life Sciences. It doesn't signal an immediate buy or sell, but rather a stable institutional presence.
Key Numbers
- 49372L100 — CUSIP Number (identifies Kezar Life Sciences Inc. common stock)
- 04-2456637 — IRS Identification No. (identifies State Street Corporation)
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Kezar Life Sciences, Inc. (company) — the subject company whose stock is being reported
- 0000093751-24-000077 (dollar_amount) — accession number for the filing
- December 31, 2023 (date) — date of event requiring the filing
Forward-Looking Statements
- State Street Corporation will likely maintain its passive investment in Kezar Life Sciences Inc. for the foreseeable future. (State Street Corporation) — high confidence, target: 2025-01-23
FAQ
What is the purpose of this SC 13G/A filing?
This SC 13G/A filing by State Street Corporation is an amendment to a previous Schedule 13G, indicating an update to their beneficial ownership of Kezar Life Sciences Inc. common stock as of December 31, 2023, under Rule 13d-1(b).
Who is the 'reporting person' in this filing?
The 'reporting person' is State Street Corporation, a financial institution with IRS Identification No. 04-2456637, located at 1 Congress Street, Boston, MA.
Which company's stock is the subject of this filing?
The subject company is Kezar Life Sciences, Inc., a pharmaceutical preparations company with CIK 0001645666, whose common stock is identified by CUSIP number 49372L100.
What was the 'date of event' that triggered this filing?
The 'date of event which requires filing of this statement' was December 31, 2023, indicating the snapshot date for the reported ownership.
Under which SEC rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b) of the Securities Exchange Act of 1934, which typically applies to institutional investors who acquire beneficial ownership of more than 5% of a class of a company's equity securities in the ordinary course of business and without intent to influence control.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Kezar Life Sciences, Inc. (KZR).